Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
June 6, 2006
LONDON, June 6, 2006 - Emergent BioSolutions, a privately-held biopharmaceutical company, has signed an agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group, to develop a critically-needed vaccine to prevent one of the world's deadliest childhood diseases, serogroup B meningitis. The Covington team that advised Emergent BioSolutions in the deal was led by life sciences corporate/commercial expert Lucinda Osborne.The agreement gives sanofi pasteur exclusive, world-wide rights to Emergent BioSolutions' proprietary proteins and related technology for the development of a novel vaccine to protect against Neisseria meningitides serogroup B bacterial infections. In addition, it provides that the parties will collaborate in all aspects of product development through to regulatory approval. The companies are targeting a major unmet public health need as current vaccines do not provide protection against serogroup B meningitis.Michael Stone, head of Covington's London Life Sciences Transactional practice, comments: "This deal exemplifies the firm's continuing growth in handling industry-leading life sciences transactions and reinforces our position as a leader in the market for pharma and biotech work."Daniel J. Abdun-Nabi, Sr. VP - Legal and Corporate Affairs & General Counsel, of Emergent BioSolutions said: "Lucinda and her team have proven to be an excellent partner in our strategy of selectively establishing relationships with leading pharmaceutical and biotechnology companies for the commercialization of certain of our product candidates. The advice and service we received from Lucinda was invaluable and we look forward to working with Covington in the future."
In January 2006, Covington was voted by industry as the top law firm in the world in the area of life sciences. It topped both "The Life Sciences Industry Super League" and, for the third year running, "The Life Sciences Regulatory Super League". These rankings were published in Global Counsel magazine's January issue.